Drug Costs - Statistics & numerical data
Research News and Information

Sunday, November 22, 2009

Antiepileptic drugs in children in developing countries: research and treatment guideline needs.

8 Sep 2009 Epilepsy is the most common neurologic disorder in childhood. Effective interventions are available for treatment; however, the treatment gap in children is more than 80% in many developing countries. An important reason for this huge treatment gap ... Read more...

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

31 Aug 2009 BACKGROUND: Switching between antipsychotic medications is common in the treatment of schizophrenia. However, data on clinical and economic outcomes from antipsychotic switching, in particular acute care service use, is fairly limited. The goal of ... Read more...

AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).

30 Jul 2009 The methods by which the U.S. health care system pays for prescription drugs have faced increasing scrutiny in recent years. Two key developments have emerged: (a) congressional enactment of important changes in the basis for payments for ... Read more...

Latest indexed articles for 'Drug Costs - Statistics & numerical data'

These are the very latest articles for this heading:

• Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. 26 Oct 2009
• Cost is killing patients: subsidising effective antimalarials. 8 Oct 2009
• Antiepileptic drugs in children in developing countries: research and treatment guideline needs. 8 Sep 2009
• Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. 31 Aug 2009
• Pricing of pneumococcal vaccines under advance market commitments. 27 Aug 2009
• AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0). 30 Jul 2009
• National patterns in antidepressant medication treatment. 30 Jul 2009
• Medicare Part D update--lessons learned and unfinished business. 21 Jul 2009
• Selegiline shortage: Causes and costs of a generic drug shortage. 19 Jul 2009
• Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years. 18 Jul 2009
• [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results] 16 Jul 2009
• Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. 8 Jul 2009
• Comparison of economical aspects of interscalene brachial plexus blockade and general anaesthesia for arthroscopic shoulder surgery. 6 Jul 2009
• Second opinions improve ADHD prescribing in a medicaid-insured community population. 29 Jun 2009
• Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. 29 Jun 2009
• Revised cost estimates of Medicaid recipients with serious mental illness and HIV-AIDS. 29 Jun 2009
• The risks and costs of multiple-generic substitution of topiramate. 14 Jun 2009
• Is early intervention in psychosis cost-effective over the long term? 7 Jun 2009
• Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs. 30 May 2009
• Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. 30 May 2009

See a longer list of these articles.

Technical information about 'Drug Costs'

Definition: The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).

Descriptor UI: D016527

Alternative terms: Drug Costs; Cost, Drug; Costs, Drug; Drug Cost;

Allowable Qualifiers: classification; history; legislation & jurisprudence; standards; trends; statistics & numerical data; ethics;

Tree Number: N03.219.151.400.350; N05.300.375.300;

History Note: 92

Technical Notes: costs to a health care facility or organiz: do not confuse with FEES, PHARMACEUTICAL or PRESCRIPTION FEES which are costs to the patient